Call for Papers
Human Vaccines is a unique peer-reviewed journal that is focused exclusively on vaccines for humans
NOW INDEXED BY MEDLINE/PUBMED. Publishing monthly!
Vaccine research and development is extending its reach beyond the prevention of bacterial or viral diseases. There are experimental vaccines for immunotherapeutic purposes and for applications outside of infectious diseases, in diverse fields such as cancer, autoimmunity, allergy, Alzheimer’s and addiction. Many of these vaccines should become available in the next two decades, with consequent benefit for human health. Continued advancement in this field will benefit from a forum that can (A) help to promote interest by keeping investigators updated, and (B) enable an exchange of ideas regarding the latest progress in the many topics pertaining to vaccines.
Human Vaccines provides such a forum. It is published in a format that is accessible to a wide international audience in the academic, industrial and public sectors.
What is new in 2011:
January Issue (7-1)
Special Focus on Type-1 Diabetes Vaccines!
The first issue this year features 5 Special Focus Reviews discussing different strategies and issues for developing a therapeutic vaccine for the autoimmune disease T1D.
February Issue (7-2)
Read the critical Opinion piece by Dr. Donald Light about the funding crisis of the GAVI Alliance and the pneumococcal vaccine advanced market commitment (AMC).
January/February Supplementary Issue
Special Issue: Vaccines, Immunization and Immunotherapy
Vaccines, immunization and immunotherapy We are pleased to announce a Meeting Supplement Issue bases on the recent 7th World Congress on Vaccines, Immunisation and Immunotherapy (WCVII). Dr. Edouard Kurstak, President of the WCVII and of the Infections Control World Organization (ICWO), has kindly served as Guest Editor for this Supplement, which features over 30 selected papers prepared by speakers of the WCVII 2010.
March Issue (7-3)
Special Issue on Plant-derived Vaccines!
Dr. Maxim Golovkin from Thomas Jefferson University in Philadelphia (PA, USA) kindly agreed to serve as Guest Editor for this Special Issue, which features 10 excellent Reviews on plant-produced vaccines and antibodies.
Upcoming Special Focus: Neglected Vaccines
We invite you to send us your original manuscripts on Neglected Vaccines (closing date 6 June 2011). The appearance of your research paper in the context of a series of Reviews written by experts in the field will increase its visibility and round out these special issues!
NPP: News, Policy and Profiles
We have extended our News & Policy section to also include Profiles of vaccine-related organizations. Profiles appear in the format of an interview and may describe private companies, academic, governmental or non-governmental organizations. If you would like to see your company/organization being profiled in Human Vaccines, please contact Eva Riedmann.
The NPP section covers the latest developments in the world of vaccines in all segments from research to clinical to public health, academia and government, biotech and industry, and in addition report on relevant events and awards. This new monthly section will continue throughout 2011 and beyond.
We will accept News and Policy/Opinion articles for NPP on shorter notice than for our regular articles in order that the content of this section can be as current as possible.
Human Vaccines utilizes an online submission and peer review tracking system which is designed to provide a better, more efficient service to authors and reviewers.
• Authors can submit manuscripts online from anywhere in the world.
• Authors can track their manuscript through the peer review process.
• Author files are automatically converted into a PDF file and submissions are acknowledged by email.
• Editors and reviewers access the PDF files on the website.
Original Contributions can cover the areas of research, development, clinical, regulatory, production, use in the field, perceptions, safety, etc. Original Contributions are published as full-length reports or as brief contributions.
Solicited and submitted Commentaries and Reviews on significant developments are published. Special features such as the Portrait of a Leading Vaccinologist, regular Meeting Reports on important conferences in the field, Product Reviews and Editor’s Corner round out the offerings of Human Vaccines.
Each contribution is reviewed rigorously by two vaccine experts who are either Associate Editors or are recruited by the Editor-in-Chief or Editors. For Original Conributions, the primary criteria for publication are originality, scientific merit, and general interest in the field. Our Editorial Board members and Associate Editors, who are outstanding investigators from around the world, strive to maintain the highest standards of excellence in order to generate a valuable resource for our international readership.
The Editors undertake to provide a peer-review response on each submission within 30 days following submission, and a final decision within 7 days after resubmission of a revised manuscript.
Please become part of our growing journal by submitting your Original Contribution, Commentary or Review.
Please see our submission guidelines: www.landesbioscience.com/journals/vaccines/guidelines